BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 30

• Drug Development

  Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

  Dyne Therapeutics, Inc today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS).

  June 24, 2024

   · 

  6 min read
• Drug Development

  Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association

  Viking Therapeutics, Inc. today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association.

  June 24, 2024

   · 

  6 min read
• Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference

  Clene Inc. today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspective Virtual Conference and host 1x1 investor meetings.

  June 24, 2024

   · 

  1 min read
• Drug Development

  Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial

  Biond Biologics Ltd. today announced that the first patient has been dosed in a first-in-human clinical trial testing BND-35, a humanized ILT3/LILRB4 antagonist antibody.

  June 24, 2024

   · 

  4 min read
• BioMidwest

  Avenacy Announces Launch of Tranexamic Acid Injection, USP in the U.S. Market

  Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Tranexamic Acid Injection, USP in the United States as a therapeutic generic equivalent for Cyklokapron® as approved by the U.S. Food and Drug Administration.

  June 24, 2024

   · 

  2 min read
• FDA

  Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer

  Oncoinvent Receives FDA Fast Track Designation for Radspherin ® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer.

  June 24, 2024

   · 

  3 min read